We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Armodafinil (Nuvigil)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Armodafinil (Nuvigil) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2006–2020 with a typical study size of 254 participants.
Based on 8 studies · 1 meta-analysis · 4 RCTs · 883 total participants
Confidence
ModerateBy outcome
Armodafinil (Nuvigil) has an evidence score of 5/10 — emerging evidence based on 8 indexed studies, including 1 meta-analysis. A prescription wakefulness-promoting drug (Nuvigil) — the longer-acting R-enantiomer of modafinil — approved for the excessive sleepiness of narcolepsy, shift-work disorder, and residual sleepiness in treated obstructive sleep apnea. Used off-label as a 'smart drug' for wakefulness and cognition, but the off-label cognitive benefit in healthy people is modest and task-dependent (the same picture as modafinil), and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug. Representative study: PMID 28590365.
The commonly studied dose of Armodafinil (Nuvigil) is Approved dosing is 150–250 mg once daily in the morning for narcolepsy and OSA, or 150 mg taken ~1 hour before the start of a night shift for shift-work disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Modafinil
Mostly mechanism / observationalA prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Armodafinil (Nuvigil) — longer-acting R-enantiomer of modafinil
A prescription wakefulness-promoting drug (Nuvigil) — the longer-acting R-enantiomer of modafinil — approved for the excessive sleepiness of narcolepsy, shift-work disorder, and residual sleepiness in treated obstructive sleep apnea. Used off-label as a 'smart drug' for wakefulness and cognition, but the off-label cognitive benefit in healthy people is modest and task-dependent (the same picture as modafinil), and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Armodafinil has strong pivotal-RCT evidence for its approved sleep-disorder indications (narcolepsy, residual sleepiness in treated OSA, shift-work disorder), but the popular off-label cognitive-enhancement use is supported only by modest, task-dependent effects (the same picture as modafinil), its adjunct-in-bipolar-depression effect is modest (Cohen d ~0.28), it is not a longevity drug, and it carries a rare but serious skin-reaction (SJS/TEN) warning — so the off-label use stays emerging.
Armodafinil is the purified longer-half-life R-enantiomer of modafinil — a eugeroic, or wakefulness-promoting agent.
Because the R-isomer is cleared more slowly than the S-isomer, armodafinil sustains higher plasma concentrations later in the day than an equivalent dose of racemic modafinil, which is the basis for its once-daily dosing.
Like modafinil it raises cortical catecholamine tone (weak dopamine-transporter inhibition) and indirectly engages the orexin (hypocretin) and histamine arousal systems.
Its approved uses are well-evidenced by pivotal placebo-controlled RCTs: in narcolepsy (Harsh, 2006), as adjunct for residual excessive sleepiness in nCPAP-treated obstructive sleep apnea (Roth, 2006), and in shift-work disorder (Czeisler, 2009) — all showing significant improvement in objective wakefulness (Maintenance of Wakefulness Test) and clinical global impression.
Off-prescription, armodafinil is taken as a cognitive enhancer or 'smart drug', and the honest distinction is the same one that applies to modafinil: in healthy, non-sleep-deprived adults the cognitive benefit is modest and task-dependent, not the transformative enhancement its reputation implies.
Beyond sleep medicine it has been tested as an adjunct in bipolar I depression, where a large RCT (Calabrese, 2014) found only a modest effect (Cohen d ≈ 0.28) and a stimulant-class meta-analysis (McIntyre, 2017) judged the antidepressant evidence modest and methodologically limited.
Armodafinil is not a longevity or healthspan drug — there is no lifespan or geroprotective evidence.
Its abuse/dependence liability is low relative to classic stimulants, but it is not benign: the label carries a serious warning for rare but life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis — a confirmed case has been reported), plus psychiatric effects, and it induces CYP3A4 (reducing hormonal-contraceptive efficacy).
The score reflects genuinely strong evidence for its approved sleep-disorder indications against a modest, task-dependent off-label cognitive benefit and a real serious-rash risk.
Like modafinil, increases cortical catecholamine levels (weak dopamine-transporter inhibition raising synaptic dopamine and noradrenaline) — the core of its wake-promoting action.
Indirectly activates orexin (hypocretin) neurons and the tuberomammillary histamine system, engaging the brain's intrinsic arousal pathways.
The purified R-isomer is cleared more slowly than the S-isomer, sustaining higher late-day plasma concentrations than equivalent racemic modafinil and supporting once-daily dosing.
How Armodafinil (Nuvigil) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved dosing is 150–250 mg once daily in the morning for narcolepsy and OSA, or 150 mg taken ~1 hour before the start of a night shift for shift-work disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (armodafinil) | Recommended |
| 💊Modafinil (the racemate with the deepest trial base across narcolepsy, shift work, and OSA) | Alternative |
Armodafinil is the longer-acting R-enantiomer; the racemate modafinil has the broader and older trial base.
Compare Armodafinil (Nuvigil) vs Modafinil →Minimum: 1 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Once daily in the morning for narcolepsy/OSA, or before a night shift for shift-work disorder; avoid late-day dosing because of the long half-life and sustained late-day levels.
Dose-response data unavailable. The current published research for Armodafinil (Nuvigil) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In narcolepsy, residual sleepiness in nCPAP-treated OSA, and shift-work disorder, armodafinil significantly improves objective wakefulness (Maintenance of Wakefulness Test) and clinical global impression.
Off-label, benefits in healthy adults are modest and task-dependent — the same picture established for modafinil, most consistent under demanding or sleep-deprived conditions.
As an adjunct in bipolar I depression the effect was modest (Cohen d ~0.28), and stimulant-class syntheses judge the antidepressant evidence modest and methodologically limited — the 'smart drug' reputation outruns the evidence.
Headache, insomnia, and nausea are common; rare but life-threatening skin reactions (SJS/TEN — a confirmed case is reported) and psychiatric effects can occur.
Use additional/alternative contraception during and for ~1 month after armodafinil (CYP3A4 induction lowers efficacy).
Use with caution — eugeroics can precipitate mania, psychosis, or anxiety.
Caution with uncontrolled hypertension or arrhythmia; monitor blood pressure and heart rate.
Armodafinil induces CYP3A4 and can reduce contraceptive efficacy — additional/alternative contraception is advised during and for ~1 month after use.
Inhibits CYP2C19 and alters other enzymes — can raise levels of warfarin, phenytoin, and similar drugs; monitor.
Tip: Most frequent adverse effect in trials; often dose-related and transient.
Tip: Dose in the morning; reduce dose if sleep or anxiety is affected.
Tip: Stop immediately and seek emergency care at the first sign of rash, blistering, or mucosal involvement; a confirmed SJS case after armodafinil is reported, and risk is highest early in treatment.
Tip: Caution in those with a psychiatric history; discontinue and seek care if new psychiatric symptoms emerge.
The best time to take Armodafinil (Nuvigil) is in the morning. It can be taken on an empty stomach. Long half-life and sustained late-day levels (the point of the R-enantiomer) mean morning dosing avoids disrupting nighttime sleep; shift-work use is dosed before the shift.
Armodafinil (Nuvigil) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are headache, insomnia / nausea / nervousness, serious skin reaction (Stevens-Johnson syndrome / TEN). Use caution if any of these apply to you: Prior hypersensitivity or serious skin reaction to armodafinil/modafinil; History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant use; Uncontrolled hypertension or arrhythmia (use with caution).
Adrafinil (Olmifon)
Mostly mechanism / observationalA discontinued French wakefulness drug (Olmifon, CRL-40028) the liver converts into modafinil — essentially a less-efficient, slower way to take modafinil. Once prescribed for vigilance and attention in the elderly, it was withdrawn from the market and now circulates grey-market as an unregulated 'nootropic.' Direct human evidence is old and thin, chronic use can raise liver enzymes, and it is NOT a dietary supplement and NOT a longevity drug.
Additive cardiovascular and CNS stimulation; use with caution.